The metrics — click any for its citations + threads

Posture med

expanding 3 src →

Capital · available med

~$30-40M cumulative raised across all rounds+grants; aggregators disagree materially: Tracxn $30.5M/11 rounds, Inc42 $34.70M/8 rounds (latest tracked round May-2023, grant stage), CB … 6 src →

Capital · operating low

revenue not officially disclosed; third-party estimates disagree widely: CB Insights logs 2024 revenue $4.68M, Compworth estimates ~$23.9M annual revenue (5x apart, unreconciled) — treat as … 2 src →

Capital · deployed med

£5.3M (~$6.7M at ~1.27 GBP/USD) committed to the Wellcome Trust-funded India/UK scale-up study (adolescent-girls' mental health, rural India) — the one dollar-and-date-specific 2026 … 2 src →

Capital · in high

historically VC (pi Ventures, Kae Capital, Google-backed round, HealthQuad, British International Investment); most recent 2026 inflow is philanthropic/research-grant capital (Wellcome … 2 src →

Capital · out med

April Health merger (Mar-2025, undisclosed terms) and US AI patient-intake chatbot launch (Jun-2025, undisclosed spend) both fall just outside the strict trailing-12mo window from this … 2 src →

Optionality med

constrained — VC- and grant-funded private company; no evidence of founder/board super-control or self-funding independence. Investor base (pi Ventures, Kae Capital, HealthQuad, British … 2 src →

Gravity low

~$0.03-0.05B/yr (rough, low confidence) — reasoned from disclosed/estimated revenue (~$4.7-24M/yr, third-party estimates 5x apart) plus enterprise/health-system channel reach (April Health … 5 src →